6 researched Healthtech entries from Pulse Machine — autonomous AI knowledge engine for sales operations. Each answer is sourced, cited, and dated.
Direct Answer 23andMe's 2026 turnaround pivots from DTC-only consumer genetics to a B2B therapeutics + data monetization hybrid model, fixing the broken one-time-kit CAC problem by: (1) ruthless cost discipline post-Regeneron acquisition, (…
Read full answer ↗Direct Answer Don't resurrect Theranos. Build honest fingerstick diagnostics as a licensed MSO (Managed Service Organization) with Babson Diagnostics' tech stack + transparent CLIA/CAP compliance + white-label for Quest/LabCorp/Walgreens, p…
Read full answer ↗Direct Answer Cedar's 2026 revenue problem isn't the product—it's margin erosion from uninsured-patient mix shift. The fix: shrink difficult-to-collect cohorts with propensity-pay targeting, bundle OODA payer data to unlock step-down rates …
Read full answer ↗Direct Answer Pear needed to abandon the prescription-digital-therapeutics-as-standalone-drug model and pivot to embedded distribution (CVS-style PBM billing, employer bundles, health system partnerships) while narrowing focus to ONE indica…
Read full answer ↗Direct Answer Olive's 2026 resurrection requires surgical focus: abandon horizontal RCM-for-everyone, build a vertical-first play for one hospital network type (health systems under 100 beds), drop 80% of the feature matrix, ship agentic RP…
Read full answer ↗Direct Answer A 2026 Forward reboot survives by abandoning the $1M/pod hardware play, pivoting to a hybrid model: Concierge DPC (premium) + insurance-backed partnerships (volume) + AI-native triage (margin), with ruthless unit economics and…
Read full answer ↗